SCHEMBL16237492

SCHEMBL16237492

CCOC(=O)c1c(CN2C3COC[C@H]2CC(CC(=O)O)C3)nc(-c2nccs2)nc1-c1ccc(F)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 12/20 0.42
▸ CDC7 O00311 1/20 0.39
▸ DBF4 Q9UBU7 1/20 0.39
▸ CYP2D6 P10635 1/20 0.34
▸ CCR3 P51677 1/20 0.34
▸ HCRTR1 O43613 4/20 0.32
▸ HCRTR2 O43614 4/20 0.32
▸ HDAC3 O15379 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16237619 0.93 CYP2D6 (0.36) KCNH2CDC7DBF4CYP2D6CCR3
SCHEMBL16237458 0.87 KCNH2 (0.35) KCNH2CDC7DBF4CYP2D6CCR3
SCHEMBL16237122 0.86 CYP2D6 (0.35) KCNH2CDC7DBF4CYP2D6CCR3
SCHEMBL16237160 0.86 KCNH2 (0.35) KCNH2
SCHEMBL16237808 0.85 CYP2D6 (0.36) KCNH2CYP2D6CCR3HCRTR1HCRTR2
SCHEMBL16237558 0.85 CYP2D6 (0.38) KCNH2CDC7DBF4CYP2D6CCR3
SCHEMBL16236918 0.84 CYP2D6 (0.38) KCNH2CDC7DBF4CYP2D6CCR3
SCHEMBL16237555 0.83 CYP2D6 (0.41) KCNH2CDC7DBF4CYP2D6CCR3
SCHEMBL16237752 0.83 CYP2D6 (0.36) KCNH2CDC7DBF4CYP2D6CCR3
SCHEMBL16237164 0.83 KCNH2 (0.39) KCNH2CDC7DBF4CYP2D6CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997032-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2016-03-23 — — EP claimed
WO-2014184328-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2014-11-20 — — WO claimed
EP-2997032-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2016-03-23 — — EP disclosed
WO-2014184328-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2014-11-20 — — WO disclosed
Send feedback